Michelle LeRoux Williams - Aug 12, 2024 Form 4 Insider Report for ELUTIA INC. (ELUT)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Jeffrey Hamet, Attorney-in-Fact for Michelle LeRoux Williams
Stock symbol
ELUT
Transactions as of
Aug 12, 2024
Transactions value $
-$44,872
Form type
4
Date filed
8/13/2024, 05:00 PM
Previous filing
Jun 12, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELUT Class A Common Stock Options Exercise +50K +292.4% 67.1K Aug 12, 2024 Direct F1, F2
transaction ELUT Class A Common Stock Tax liability -$44.9K -15.8K -23.55% $2.84 51.3K Aug 12, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELUT Restricted Stock Units Options Exercise $0 -50K -100% $0.00* 0 Aug 12, 2024 Class A Common Stock 50K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.
F4 On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. The restricted stock units vested on the 10th business day following the clearance by the U.S. Food & Drug Administration ("FDA") of the Company's CanGarooRM antibiotic-eluting biologic envelope, unless such date is not during one of the Company's open trading windows, in which case such RSUs vested as of the first business day of the next open trading window. The CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, was cleared by the FDA on June 14, 2024 and the first business day of the next open trading window was August 12, 2024.